Press Release

Seraxis Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy.

admin

November 12, 2018

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.

Seraxis Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy.

About Seraxis, Inc.

Generation and selection of pluripotent stem cells for robust differentiation to insulin-secreting cells capable of reversing diabetes in rodents.

Concise Review: Lessons Learned from Islet Transplant Clinical Trials in Developing Stem Cell Therapies for Type 1 Diabetes.

Related articles

Seraxis announces closing of second VC tranche and successful completion of preclinical studies of pancreatic organoids from Seraxis’ novel pancreas-derived stem cells.

Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.

Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD.